Altimmune Inc. has come under scrutiny from investors after weight loss data from a phase Ib trial of its nonalcoholic fatty liver disease drug, pemvidutide, sent its shares on a roller coaster ride.
Research led by the University of Texas Southwestern Medical Center reveals a protein signature that can reliably predict whether patients with nonalcoholic fatty liver disease (NAFLD) are likely to develop hepatocellular carcinoma, the most common form of liver cancer.
With the rates of nonalcoholic steatohepatitis (NASH) rapidly rising, Glympse Bio Inc. and Laboratory Corp. of America Holdings Inc. (Labcorp) have announced new tests that can assess the risk of the liver condition without the traditional biopsy.
Genome sequencing initiated to investigate how chronic liver disease leads on to hepatocellular carcinoma has instead uncovered mutations that impact fat metabolism and reduce the sensitivity of hepatocytes to insulin.
Shares of Cohbar Inc. (NASDAQ:CWBR) hit a 52-week high on Aug. 11 following news that a mitochondrial peptide analogue it is testing for the potential treatment of nonalcoholic steatohepatitis (NASH) and obesity, CB-4211, delivered "robust" improvements in key biomarkers of liver damage and glucose levels vs. placebo during a small phase Ia/Ib study.
LONDON – Technology commercialization specialist Eurekare SA has arrived on the scene after raising a $60 million series A, with which it plans to seed fund the formation of microbiome and synthetic biology startups and invest in later-stage rounds of companies specializing in those two fields.
Fractyl Laboratories Inc. has released data from a mixed meal tolerance study that shows its procedure for resurfacing the duodenal mucosa improves fasting blood glucose and reduces liver fat.
